Trial · NCT01150461
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01150461, Phase 2, Completed, Massachusetts General Hospital; results first posted 2013-09-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy. Trials, record NCT01150461. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01150461
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
- NCT number
- NCT01150461
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- losartan, placebo
- First posted
- 2010-06-25
- Last updated
- 2013-09-05
- Results first posted
- 2013-09-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. | Baseline and 1 year | |
| Secondary | Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging. | Baseline and 1 year |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. | Baseline and 1 year | Percentage change in fibrotic myocardium | MEAN | |
| SECONDARY | Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging. | Baseline and 1 year | Percentage change in LV mass | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. | Losartan 50 mg PO BID | -23 | Standard Deviation 45 | Percentage change in fibrotic myocardium | |
| Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. | Placebo | 31 | Standard Deviation 26 | Percentage change in fibrotic myocardium | |
| Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging. | Losartan 50 mg PO BID | -5 | Inter-Quartile Range 11 | Percentage change in LV mass | |
| Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging. | Placebo | 5 | Inter-Quartile Range 28 | Percentage change in LV mass |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Losartan 50 mg BID | 11 | |
| Overall Study | STARTED | Placebo | 9 | |
| Overall Study | COMPLETED | Losartan 50 mg BID | 11 | |
| Overall Study | COMPLETED | Placebo | 9 | |
| Overall Study | NOT COMPLETED | Losartan 50 mg BID | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Losartan 50 PO mg BID | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Losartan 50 PO mg BID | 0 | 11 |
| Total, other adverse events | Placebo | 0 | 9 |
| Total, serious adverse events | Losartan 50 PO mg BID | 0 | 11 |
| Total, serious adverse events | Placebo | 0 | 9 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24621999 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Losartan 50 PO mg BID vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01150461
GET https://conductscience.org/api/trials/v1/NCT01150461/registered